secwatch.observer — SEC 8-K summary
======================================

Issuer:     PharmaCyte Biotech, Inc. (PMCB)
CIK:        0001157075
Form:       8-K
Filed at:   2023-11-24T23:59:59+00:00
Accession:  0001683168-23-008446
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

PharmaCyte grants $100K cash and 170K options to CEO, $50K cash and 85K options to CFO
--------------------------------------------------------------------------------

- One-time grant to Joshua Silverman (Interim CEO): $100,000 cash and options to purchase 170,000 shares at $2.18/share.
- One-time grant to Carlos Trujillo (CFO): $50,000 cash and options to purchase 85,000 shares at $2.18/share.
- Options vest 50% on grant date (Nov 20, 2023) and 50% on one-year anniversary.
- Grants made under the PharmaCyte Biotech 2022 Equity Incentive Plan.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1157075/000168316823008446/0001683168-23-008446-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1157075/000168316823008446/pharmacyte_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-23-008446

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer